UBS AM
NVCR icon

UBS AM’s NovoCure NVCR Stock Holding History

UBS AM’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.49M Buy
228,269
+1,769
+0.8% +$22.1K ﹤0.01% 1937
2025
Q4 		$2.93M Sell
226,500
-969,124
-81% -$12.4M ﹤0.01% 1721
2025
Q3 		$15.4M Sell
1,195,624
-175,907
-13% -$2.35M ﹤0.01% 927
2025
Q2 		$24.4M Sell
1,371,531
-410,628
-23% -$7.16M ﹤0.01% 971
2025
Q1 		$31.8M Buy
1,782,159
+1,080,514
+154% +$24.5M 0.01% 785
2024
Q4 		$20.9M Sell
701,645
-206,354
-23% -$4.37M ﹤0.01% 927
2024
Q3 		$14.2M Buy
907,999
+84,606
+10% +$1.53M ﹤0.01% 1080
2024
Q2 		$14.1M Buy
823,393
+688,510
+510% +$12.1M ﹤0.01% 998
2024
Q1 		$2.11M Buy
134,883
+6,011
+5% +$88.4K ﹤0.01% 1668
2023
Q4 		$1.92M Buy
128,872
+10,042
+8% +$134K ﹤0.01% 1713
2023
Q3 		$1.92M Sell
118,830
-307,608
-72% -$8.87M ﹤0.01% 1648
2023
Q2 		$25.6M Hold
426,438
– – 0.01% 709
2023
Q1 		$25.6M Sell
426,438
-7,942
-2% -$635K 0.01% 709
2022
Q4 		$31.9M Buy
434,380
+29,102
+7% +$2.19M 0.02% 652
2022
Q3 		$30.8M Sell
405,278
-25,542
-6% -$1.99M 0.02% 662
2022
Q2 		$29.9M Buy
430,820
+118,577
+38% +$8.93M 0.02% 651
2022
Q1 		$25.9M Sell
312,243
-15,028
-5% -$1.11M 0.01% 770
2021
Q4 		$24.6M Buy
327,271
+12,510
+4% +$1.26M 0.01% 850
2021
Q3 		$36.6M Buy
314,761
+745
+0.2% +$113K 0.02% 717
2021
Q2 		$69.7M Buy
314,016
+31,106
+11% +$6.05M 0.03% 549
2021
Q1 		$37.4M Buy
282,910
+60,631
+27% +$9.59M 0.02% 693
2020
Q4 		$38.5M Buy
222,279
+112,421
+102% +$15.4M 0.02% 671
2020
Q3 		$12.2M Buy
109,858
+9,902
+10% +$792K 0.01% 886
2020
Q2 		$5.93M Sell
99,956
-119,148
-54% -$7.84M ﹤0.01% 1053
2020
Q1 		$14.8M Sell
219,104
-22,470
-9% -$1.78M 0.01% 759
2019
Q4 		$20.4M Sell
241,574
-108,486
-31% -$8.76M 0.01% 772
2019
Q3 		$26.2M Buy
350,060
+5,197
+2% +$416K 0.02% 692
2019
Q2 		$21.8M Buy
344,863
+1,064
+0.3% +$53.9K 0.02% 737
2019
Q1 		$16.6M Sell
343,799
-32,732
-9% -$1.58M 0.01% 785
2018
Q4 		$12.6M Sell
376,531
-55,499
-13% -$2.03M 0.01% 811
2018
Q3 		$22.6M Buy
432,030
+19,077
+5% +$759K 0.02% 719
2018
Q2 		$12.9M Buy
+412,953
New +$11.5M 0.01% 883

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

UBS AM's NVCR Position: Q1 2026 in Review

UBS AM increased its NovoCure (NVCR) stake by 0.78% in Q1 2026, buying an estimated $22.1K and bringing the position to 228,269 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

UBS AM first reported a position in NVCR in Q2 2018 and has held it in 32 quarters since. The position peaked at $69.7M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • UBS AM held 228,269 shares of NovoCure worth $2.49M as of Q1 2026.
  • UBS AM bought 1,769 NovoCure shares in Q1 2026, an estimated $22.1K.
  • NovoCure made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1937 holding.
  • UBS AM first reported a position in NovoCure in Q2 2018 and has held it in 32 quarters since.
  • UBS AM's NovoCure position peaked at $69.7M in Q2 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.